Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 12/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL348743 | 0.80 | HSD11B1 (0.73) | HSD11B1CYP2D6AVPR1ANPY5R | |
| SCHEMBL350891 | 0.80 | HSD11B1 (0.73) | HSD11B1CYP2D6AVPR1ANPY5R | |
| SCHEMBL12576639 | 0.80 | HSD11B1 (0.58) | HSD11B1CYP2D6AVPR1ANPY5R | |
| SCHEMBL3892280 | 0.74 | IMPDH2 (0.38) | HSD11B1 | |
| SCHEMBL348512 | 0.73 | HSD11B1 (0.76) | HSD11B1CYP2D6AVPR1ANPY5R | |
| SCHEMBL3886304 | 0.73 | IMPDH2 (0.36) | — | |
| SCHEMBL4757345 | 0.72 | HSD11B1 (0.64) | HSD11B1CYP2D6AVPR1ANPY5R | |
| SCHEMBL4757352 | 0.72 | HSD11B1 (0.64) | HSD11B1CYP2D6AVPR1ANPY5R | |
| SCHEMBL347562 | 0.72 | HSD11B1 (1.00) | HSD11B1CYP2D6 | |
| SCHEMBL350329 | 0.72 | HSD11B1 (1.00) | HSD11B1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013163-A1 | TETRASUBSTITUTED UREAS AS MODULATORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE 1 | Incyte Corporation (US) | 2009-01-14 | — | — | EP | claimed |
| WO-2007130898-A1 | TETRASUBSTITUTED UREAS AS MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1 | INCYTE CORPORATION (US) | 2007-11-15 | — | — | WO | claimed |
| US-8871208-B2 | 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof | ABBVIE INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871208-B2 | 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof | ABBVIE INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| US-20070293529-A1 | Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1 | INCYTE CORPORATION | 2007-12-20 | — | — | US | disclosed |
| US-20070293529-A1 | Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1 | INCYTE CORPORATION | 2007-12-20 | — | — | US | disclosed |
| WO-2007130898-A1 | TETRASUBSTITUTED UREAS AS MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1 | INCYTE CORPORATION (US) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293529-A1 | Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD17B11 | HSD11B1 1/4885CYP2D6 304/4885AVPR1A 2572/4885 |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885CYP2D6 244/4885AVPR1A 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.